Targeted therapies in the treatment of advanced/metastatic NSCLC
(2009) European Journal of Cancer — Vol. 45, n° 14, p. 2473-2487 (2009)
Files
pdfdocument.pdf
Restricted Access - Adobe PDF
- 235.68 KB
Details
- Authors
- Abstract
- The treatment of advanced non-small cell lung cancer (NSCLC) has evolved substantially during the last years. Chemotherapy remains the cornerstone of treatment and prolongs survival with a positive impact on quality of life. However, we seem to have reached a plateau of activity in the treatment of NSCLC. Recently, the addition of bevacizumab or cetuximab to chemotherapy doublets has improved the outcome in selected patients with advanced NSCLC. Furthermore, the use of erlotinib and gefitinib is an alternative for second line treatment. Advances in our understanding of molecular biology of cancer and mechanisms of tumourigenesis have further enabled the discovery of several potential molecular targets and development of novel 'targeted therapies'. The purpose of this study is to review current data on the role of targeted therapies in the treatment of advanced NSCLC. (C) 2009 Elsevier Ltd. All rights reserved.
- Affiliations
Citations
Pallis, A. G., Serfass, L., Dziadziusko, R., van Meerbeeck, J. P., Fennell, D., Lacombe, D., Welch, J., & Gridelli, C. (2009). Targeted therapies in the treatment of advanced/metastatic NSCLC. European Journal of Cancer, 45(14), 2473-2487. https://doi.org/10.1016/j.ejca.2009.06.005 (Original work published 2009)